Versions Compared

Old Version 1

changes.mady.by.user Lydia Foeken

Saved on

compared with

New Version Current

changes.mady.by.user Eefke van Eerden

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

BACKGROUND

A novel coronavirus (later named SARS-CoV-2, with the resulting illness named COVID-19) emerged in late 2019, with WHO declaring a global health emergency on 30 January 2020. The epidemic has since spread to all populated continents, with a global pandemic declared on 11 March 2020.

Public health measures against the COVID-19 pandemic have varied widely in strategy and success around the world.  Travel restrictions in particular are presenting major challenges in logistics and transport for donated haemopoietic progenitor cells.  Meanwhile there remains no evidence that SARS-CoV-2 is transmissible via blood or HPCs from a healthy donor lacking symptoms of COVID-19.



REFERENCES

WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

ECDC: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-outbreak-acute-respiratory-syndrome-associated-novel-1

EBMT: https://www.ebmt.org/covid-19-and-bmt

COVID-19 is presenting major logistical challenges in managing and assessing HPC donors and in collecting and transporting HPC products.  WMDA has developed a publicly-available resource page at https://share.wmda.info/x/Yj6OF.

Contents

Condition

Atherosclerotic or thrombotic occlusion of the coronary vasculature.

Pseudonyms and other related conditions include:

Angina

Ischaemic heart disease (IHD)

Myocardial infarction (MI)

Heart attack

Guidance at RECRUITMENT for adult volunteer donor (NA for maternal donor (cord blood donation))

UNACCEPTABLE

Guidance at CT/WORK-UP

UNACCEPTABLE, PERMANENT DEFERRAL

Individual at Risk

Donor

Justification

Myocardial infarction and angina have been well-documented as complications of both bone marrow and mobilised stem cell collection. In donors with known coronary artery disease, both processes pose an unacceptable risk to donor.

References

Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94(1): 94-101.